|1.||Morton, Donald L: 10 articles (02/2012 - 08/2002)|
|2.||Essner, Richard: 5 articles (11/2007 - 08/2002)|
|3.||Hsueh, Eddy C: 4 articles (10/2004 - 10/2002)|
|4.||Hoon, Dave S B: 3 articles (02/2012 - 10/2002)|
|5.||Ye, Xing: 3 articles (11/2007 - 12/2002)|
|6.||Gupta, Rishab K: 3 articles (01/2003 - 08/2002)|
|7.||Foshag, Leland J: 3 articles (12/2002 - 08/2002)|
|8.||O'Day, Steven J: 3 articles (12/2002 - 08/2002)|
|9.||Wang, He-Jing: 2 articles (02/2012 - 10/2002)|
|10.||Faries, Mark B: 2 articles (02/2012 - 01/2005)|
|1.||Melanoma (Melanoma, Malignant)
02/01/2012 - "After complete metastasectomy, patients were prospectively enrolled in a randomized trial of adjuvant therapy with a whole-cell melanoma vaccine, Canvaxin, plus Bacille Calmette-Guerin (BCG) versus placebo plus BCG. "
01/01/2005 - "Recently, a phase III trial evaluating the Canvaxin whole-cell vaccine in stage IV melanoma was halted because of a low likelihood of significant benefit. "
10/01/2004 - "This finding will be evaluated in a multicenter phase III trial of Canvaxin plus bacille Calmette-Guerin (BCG) versus placebo plus BCG after resection of stage III melanoma."
01/01/2004 - "Matched-pair analyses of data from extensive phase II trials have demonstrated a consistent overall survival (OS) benefit for Canvaxin therapy in stage IV melanoma (five-year OS of 39% for 107 vaccine patients versus 20% for 107 non-vaccine patients; P = .0009) and stage III melanoma (five-year OS of 49% for 739 vaccine patients versus 37% for 739 non-vaccine patients; P = .0001). "
10/01/2002 - "In 1984, the authors began phase II trials of Canvaxin PV as postsurgical adjuvant therapy for AJCC stage III melanoma. "
12/01/2003 - "The cumulative data for Canvaxin therapeutic polyvalent cancer vaccine represent the largest phase II clinical trial of any cancer vaccine. "
12/01/2002 - "Prolonged survival was observed in patients who received postoperative active immunotherapy with Canvaxin therapeutic cancer vaccine. "
10/01/2004 - "We randomly selected 54 patients from a study of Canvaxin therapy after complete resection of American Joint Committee on Cancer (AJCC) stage III melanoma. "
01/01/2004 - "Immune response to postsurgical adjuvant active immunotherapy with Canvaxin polyvalent cancer vaccine: correlations with clinical course of patients with metastatic melanoma."
02/01/2004 - "Technology evaluation: Canvaxin, John Wayne Cancer Institute/CancerVax."
|3.||Colonic Neoplasms (Colon Cancer)
02/01/2004 - "Canvaxin is currently undergoing phase III clinical trials for melanoma and a phase II trial for colon cancer."
02/01/2004 - "CancerVax and the John Wayne Cancer Institute are co-developing Biotechnology Tumor antigen Canvaxin, a vaccine containing over 20 tumor antigens, for the potential treatment of melanoma and colon cancer. "
01/01/2004 - "In 77 patients who received Canvaxin vaccine after resection of stage IV melanoma, five-year OS rate was 75% for patients with an elevated level of IgM antibodies against a 90-kD glycoprotein antigen (TA90) expressed by the vaccine, and a strong delayed-type hypersensitivity (DTH) response to the vaccine; by contrast, survival was 36% for patients who had either an elevated IgM response or a strong DTH response, and only 8% if neither response was strong (P < .001). "
|1.||polyvalent melanoma cell vaccine
|6.||Immunoglobulin M (IgM)
|8.||Neoplasm Antigens (Tumor Antigens)